Arnatar Therapeutics
PrivateLast Round
Series A
Apr 8, 2024
Total Funding Raised
$118.45M
Momentum
Top 1%
of companies Caplight tracks
Company Overview
Arnatar Therapeutics is a biotechnology company that develops RNA-based therapies using its proprietary DARGER platform to silence disease drivers or restore protein function for the treatment of cardiometabolic, liver, kidney, and central nervous system diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Arnatar Therapeutics Comparables
Compare Arnatar Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Sanegene Bio | 78% | |
| Orfonyx Bio | 75% | |
| Harness Therapeutics | 71% | |
Arnatar Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Apr 8, 2024 | ||||
| Seed | Sep 19, 2022 |
Key People
Founding team and executive leadership
Arnatar Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Jifeng Ventures | Series A |
| New Alliance Capital | Series A |
| Legend Star | Series A |
| Bencao Capital | Series A |
| Eight Roads Ventures | Series A |
| Transfar Group | Series A |
| Huajin Capital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 28, 2026
Grew 55% QoQ, from 11 to 17 employees.
- Jul 26, 2026
Monthly visitors increased 44% MoM.
Arnatar Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Arnatar Therapeutics's valuation, stock price, and market status.